Digest Network Come funziona
Network
/
Società
IN
Non verificato

INVENTIVA

Di cosa scriviamo

FarmaceuticaPolitica Internazionale

28 comunicati stampa

Guarda tutti i comunicati
30/10/2024
Farmaceutica
Politica Internazionale
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
30/10/2024
Farmaceutica
Politica Internazionale
Inventiva annonce la recommandation positive du cinquième DMC de l’étude clinique NATiV3 Phase 3 avec lanifibranor dans la MASH  
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
21/10/2024
Farmaceutica
Politica Internazionale
Inventiva annonce un abstract « late breaker » sur l’essai clinique de Phase 2, LEGEND, combinant lanifibranor et empagliflozine, lors du Liver Meeting™ 2024 organisé par l’AASLD
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
21/10/2024
Farmaceutica
Politica Internazionale
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
14/10/2024
Farmaceutica
Politica Internazionale
Inventiva annonce la mise à disposition d'un prospectus dans le cadre de son financement par l’émission d’actions ordinaires et de bons de souscription d’action préfinancés
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
14/10/2024
Farmaceutica
Politica Internazionale
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
13/10/2024
Farmaceutica
Politica Internazionale
Inventiva publie son Rapport Financier Semestriel 2024 – Modalités de mise à disposition ou de consultation
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
13/10/2024
Farmaceutica
Politica Internazionale
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
13/10/2024
Farmaceutica
Politica Internazionale
Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0
13/10/2024
Farmaceutica
Politica Internazionale
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Fonte
INVENTIVA
Emittente
GLOBENEWSWIRE
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0